In Madhya Pradesh’s Chhindwara district, a tragedy that should never have happened has shaken public trust in India’s pharmaceutical system. Eleven children have died of acute kidney failure after consuming the cough syrup Coldrif, which was later found to contain dangerously high levels of diethylene glycol (DEG) — an industrial chemical known to cause renal damage and death. The prescribing doctor has been arrested, and the Tamil Nadu–based manufacturer, Sresan Pharmaceuticals, has been booked under multiple provisions of the Drugs and Cosmetics Act. Across India, states are banning the product, and regulators are racing to uncover how this contaminated syrup ever reached the market.
This catastrophe comes barely three years after the Gambia incident, where dozens of children died from DEG-contaminated Indian cough syrups. The Coldrif case suggests that despite previous alarms and international scrutiny, India’s pharmaceutical safety net remains riddled with holes.
How the Coldrif deaths unfolded across Madhya Pradesh
Between late August and early October 2025, local clinics in Parasia tehsil of Chhindwara began reporting a mysterious pattern: children with mild cold symptoms returning days later with vomiting, swelling, and reduced urine output. Within weeks, eleven children had died. Each had consumed Coldrif, a pediatric cough syrup that should have been harmless.
When the state’s Food and Drugs Administration tested samples collected from retail points, it initially reported “no contamination.” But parallel tests conducted by Tamil Nadu’s drug control authority at the Sresan Pharmaceuticals facility told a different story — the batch labeled SR-13 (manufactured in May 2025) contained 48.6 percent diethylene glycol, nearly half the bottle made up of poison.
The Union Ministry of Health later confirmed the finding, forcing Madhya Pradesh to issue a statewide ban on Coldrif. Around 433 bottles were seized from distributors, but officials acknowledged that at least 222 had already been sold to unsuspecting families. Soon after, Tamil Nadu, Rajasthan, and Kerala followed with similar bans.
As outrage spread, state authorities arrested the prescribing pediatrician, Dr. Praveen Soni, and launched criminal proceedings against Sresan Pharmaceuticals. The Central Drugs Standard Control Organisation (CDSCO) has since begun an emergency round of inspections across six states — Tamil Nadu, Himachal Pradesh, Uttarakhand, Gujarat, Maharashtra, and Madhya Pradesh — to identify systemic lapses in cough syrup manufacturing and quality control.
Why diethylene glycol is so dangerous — and how it enters medicines
Diethylene glycol is a sweet-tasting but highly toxic industrial solvent used in products such as antifreeze and brake fluid. In pharmaceuticals, it has no legitimate role. Safe formulations use propylene glycol or glycerin as solvents. However, when suppliers substitute or adulterate raw materials to cut costs, DEG can contaminate these ingredients.
Inside the human body, DEG is metabolized into diglycolic acid, a compound that attacks kidney tubules, leading to irreversible renal failure. Even small amounts can be fatal to infants. That is why the discovery of 48.6 percent DEG content in Coldrif is not mere negligence — it is a catastrophic failure of quality control that borders on criminality.
This is not an isolated incident. The Gambia tragedy in 2022 involved Indian-made syrups contaminated with DEG and ethylene glycol, killing 70 children and prompting global outrage. Similar poisonings have been recorded in Panama, Haiti, and Bangladesh in past decades, each time following the same pattern — contaminated raw solvents, weak oversight, and untraceable supply chains.
The Coldrif case is alarming not only because of its toxicity levels but because it exposes how little has changed since those earlier crises. The presence of DEG on such a scale indicates either deliberate substitution or complete breakdown in raw-material validation.
Where did the pharmaceutical system fail this time?
The tragedy exposes multiple points of failure that allowed a toxic medicine to reach children. The first is sample integrity. Madhya Pradesh’s initial tests showing “no contamination” conflict sharply with Tamil Nadu’s later findings. Such discrepancies suggest poor sampling protocols, compromised evidence handling, or a lack of standardized testing methods across state laboratories.
The second is inadequate inspection at the manufacturing stage. Under Good Manufacturing Practices (GMP), solvent purity tests and batch validation are mandatory before release. The fact that this product passed inspection means that either records were falsified or audits were not conducted.
The third failure is post-market surveillance. India lacks a robust pharmacovigilance network for over-the-counter and pediatric medicines. No automated alert went out even after multiple cases of renal failure emerged in a single district. If a reporting and correlation system had existed, these deaths might have been prevented.
Finally, accountability mechanisms are weak. Arresting one doctor does not address systemic negligence that involves multiple actors — from raw material suppliers to regulators. Experts say deterrence will come only when manufacturers face strong legal consequences and regulators are held accountable for their oversight failures.
Why India’s cough syrup problem keeps repeating
India is one of the world’s largest producers of generic drugs, exporting to more than 200 countries. Yet its regulatory landscape remains fragmented, with state drug controllers operating under uneven enforcement standards. The Coldrif case mirrors earlier scandals in which small-scale manufacturers exploited weak compliance oversight to bypass stringent testing.
Several factors fuel this recurring crisis. Many manufacturers operate on low margins, incentivizing cost-cutting. Raw material supply chains are complex, often involving multiple intermediaries who may substitute cheaper industrial-grade solvents for pharmaceutical-grade ones. Inspections, meanwhile, are infrequent and often announced in advance, limiting their deterrent effect.
The pharmaceutical industry’s reputation, once a source of national pride, now risks erosion. Each new contamination case invites skepticism from international buyers and global health agencies. Analysts warn that if India fails to restore confidence in its regulatory apparatus, it could face restrictions from importing countries and greater scrutiny from the World Health Organization.
What the government and industry must do next
The Coldrif deaths demand not just outrage but systemic reform. The government must order a full forensic audit of the manufacturing process — tracing the origin of every chemical used, the testing certificates issued, and the approval pathways followed. Transparency must become non-negotiable.
Experts are urging regulators to establish real-time quality monitoring systems where random samples of pediatric drugs are tested independently every month and results made public. Manufacturers could also be required to maintain digital traceability for solvent lots through blockchain-based supply tracking to prevent substitution at any stage.
The Drugs and Cosmetics Act should be amended to make contamination a strict-liability offense, with jail terms and cancellation of manufacturing licenses. Regulatory coordination between the CDSCO and state drug departments must be tightened to avoid conflicting test results. Above all, routine surprise inspections, independent lab testing, and whistleblower protections must become the norm, not the exception.
For the industry, this is an existential moment. Indian manufacturers must recognize that cutting corners is not sustainable in an era of global transparency. Those investing in higher standards, verified raw-material sourcing, and third-party quality audits will ultimately gain investor confidence and long-term contracts.
What this tragedy means for parents and public trust
For families in Chhindwara and Rajasthan, the pain is immeasurable. Eleven young lives have been lost, and many others remain under medical supervision. The Madhya Pradesh government has announced compensation of ₹4 lakh per victim’s family and promised free treatment for all affected children. But no amount can replace accountability.
The bigger issue is trust — can Indian parents now feel safe giving their children routine medicines? Public confidence in the health system has been shaken. The government must act decisively to reassure citizens through transparent updates, swift prosecution of the guilty, and clear labeling reforms. Pediatric medicine safety should become a national priority, with strict recall and reporting protocols for any suspect formulations.
Why this moment must lead to lasting change
The Coldrif tragedy is not an isolated local failure; it is a national warning. The systemic cracks exposed here — from manufacturing oversight to regulatory inertia — demand fundamental reform. If India wants to retain its place as the “pharmacy of the world,” it must rebuild its internal safeguards first.
This crisis should serve as a turning point for the industry, where public health and pharmaceutical integrity finally take precedence over profit margins. The deaths of eleven children must not fade into the background of policy paperwork. They must instead become the catalyst for reform that makes future Coldrifs impossible.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
